Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 32,983

Document Document Title
WO/2018/128956A1
Disclosed are systemic and intravaginal non-hormonal contraceptives comprising a spermicidal triterpenoid. The contraceptive may be in the form of a foam, cream or gel, or in unit form of a pill, vaginal contraceptive film (VCF), supposi...  
WO/2018/129369A1
Described are methods for reversible occlusion of a body lumen by way of degradation as a result of exposure to one or more stimuli such as light. The methods include administering one or more substance(s) into a body lumen of a subject ...  
WO/2018/121551A1
The present invention relates to an azabicyclo-substituted triazole derivative, a preparation method thereof, and an application of the same in medicine. In particular, the present invention relates to a novel azabicyclo-substituted tria...  
WO/2018/123680A1
In order to provide a novel means for ameliorating mastitis or improving milk production, the present invention provides a mastitis ameliorating or treating agent or a milk production promoting agent that contains a biosurfactant.  
WO/2018/123908A1
[Problem] An objective of the present invention is to provide a novel composition that can inhibit the activity of PDE5. [Solution] A composition for inhibiting phosphodiesterase-5 activity, the composition comprising a processed product...  
WO/2018/114514A1
The invention relates to the use of by cyclically-substituted uracil derivatives, on their own or in combination with other active substances, for the treatment and/or prophylaxis of illnesses, in particular for the treatment and/or prop...  
WO/2018/113694A1
The present invention relates to a condensed ring group azacyclobutyl triazole derivative, a preparation method therefor and use thereof in medicine. In particular, the present invention relates to a novel condensed ring group azacyclobu...  
WO/2018/113272A1
The present invention relates to a pharmaceutical composition comprising an oxytocin analog, a preparation method therefor, and a use thereof. The pharmaceutical composition comprises an oxytocin analog, an excipient, and a divalent meta...  
WO/2018/113273A1
A pharmaceutical composition comprising carbetocin, comprising (percent by weight): 0.5%-7% of carbetocin, 1%-10% of a water-soluble matrix material, 0.5%-5% of an amino acid anionic surfactant, 0.1%-5% of a humectant, and the balance of...  
WO/2018/108879A1
The present invention relates to a composition for use in treating symptoms relating to premenstrual syndrome (PMS). The composition for use in treating dysphoria, depression and/or mood swings relating to PMS comprises as first active i...  
WO/2018/106914A1
The subject matter of the present invention is pertinent to the field of oral delivery of pharmaceutically active agents. Embodiments of the instant invention disclose a liquid or semi-solid non-aqueous oral pharmaceutical fill compositi...  
WO/2018/100214A1
Veterinary composition for manufacturing a semen enhancer, useful for artificial insemination in animals. The present invention refers to a composition for manufacturing a semen additive characterized in that it contains oxytocin, lecire...  
WO/2018/102233A1
The invention provides compositions and methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its deriv...  
WO/2018/100533A1
The invention relates to compositions for vaginal or, alternatively, oral administration and to the use of such compositions for stabilizing the vaginal, or, alternatively, the intestinal acidity and establishing favorable conditions for...  
WO/2018/094955A1
Provided is a long non-coding RNA, PVT1, and the nucleotide sequence thereof is shown in SEQ ID NO: 1. Also provided are a pharmaceutical composition comprising PVT1, a primer for detecting PVT1 and a kit comprising the primer, an siRNA ...  
WO/2018/093369A1
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using topical application of alpha-1 adrenergic receptor agonists, muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor ag...  
WO/2018/086501A1
A novel ironing moxibustion apparatus combining moxibustion and ironing methods. Before and after use, the variation value of a grease parameter in a grease-containing Artemisia vulgaris product is less than 50% (0.5), wherein a grease c...  
WO/2018/088240A1
Provided is a method for preparing a Leydig-like cell from a human pluripotent stem cell. Further provided is a human pluripotent stem cell-derived Leydig-like cell. It is possible to prepare a Leydig-like cell by overexpressing the NR5A...  
WO/2018/086608A1
Provided are a crystalline form of a GnRH receptor antagonist and a preparation method therefor. Specifically, provided are a crystalline form I of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6- methoxypyridazin-3-yl)-4,6-d...  
WO/2018/083508A1
Oral compositions comprising as active ingredients a combination of fatty acids or esters thereof for use in a method for the treatment of repeated spontaneous abortions or repeated implantation failures after in vitro fertilization in s...  
WO/2018/082687A1
Disclosed are a polymorphic form of a GnRH receptor antagonist and a preparation method therefor. In particular, disclosed are polymorphic forms A, B, C, and D of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6- methoxypyrida...  
WO/2018/081138A1
Biodegradable contraceptive implants and methods of making and using thereof, are preferably formed of poly(ω-pentadecalactone-co-p-dioxanone) [poly(PDL-co-DO)], a family of polyester copolymers that degrade slowly in the presence of wa...  
WO/2018/076074A1
A method to increase the penetration of active agents through mucosal membranes, the method comprising the step of: a) administering to a subject in need a composition comprising: i) one or more hydrotropes in a total amount of less than...  
WO/2018/078336A1
Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a su...  
WO/2018/080353A1
The invention relates to the field of medicine and pharmaceutics, particularly to new pharmaceutical compositions for intranasal administration, comprising heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro or its pharmaceutically acceptable salin...  
WO/2018/080349A1
The invention relates to peptide chemistry, pharmacology, and medicine, and specifically to a new group of peptides having the property of stimulating sexual and genital function and having increased storage stability. For this purpose, ...  
WO/2018/073821A1
The present invention provides combined compositions and kits including Isosorbide mono-nitrate, DMI or Isosorbide dinitrate Moxisylyte, Hydralazine Arginine Norvaline, and their combinations, and a topical carrier. Methods for inducing ...  
WO/2018/070971A1
The invention relates to a pharmaceutical composition in the form of an oromucosal spray for treating erectile dysfunction and pulmonary arterial hypertension, which is non-aqueous, has a Hammett acidity value of at least 4, and comprise...  
WO/2018/069467A1
This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the ...  
WO/2018/068498A1
An oral dissolvable film of tadalafil and a preparation method therefor. The oral dissolvable film of tadalafil is prepared from tadalafil, a film-forming material, a plasticizer, an optionally existing corrective, an optionally existing...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/065076A1
The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-lik...  
WO/2018/065900A1
The present invention relates to a Feed formulation and food supplement containing Goji berries (Lycium barbarum) or extracts thereof to increase female fertility.  
WO/2018/064978A1
Uses of a bacteriostatic agent formula in preparing a composition for vaginal use. The bacteriostatic agent formula provides enhanced inhibitory effects with respect to Escherichia coli and/or Staphylococcus aureus and/or Candida. Also r...  
WO/2018/065795A1
A system of multivitamin and mineral compositions is provided for carrying out an administration regime in a woman being in the reproductive age, said system comprising compositions adjusted to the phases of the menstrual cycle and the s...  
WO/2018/064544A1
A contraceptive drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a contraceptive agent over an exten...  
WO/2018/060501A3
Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)...  
WO/2018/064468A1
Disclosed herein are methods and compositions for treating, inhibiting, or reducing hair loss, treating, inhibiting, or reducing pigmentation loss, improving or stimulating hair growth, and/or improving or stimulating pigmentation produc...  
WO/2018/060174A1
The invention relates to substituted benzimidazoles of formula (I), to the use thereof for treating and/or preventing diseases, and to the use thereof for producing drugs for treating and/or preventing diseases, in particular for treatin...  
WO/2018/064238A1
The addition of a salt to an ALA formulation reduces the degree of burning or irritation from ALA exposure during administration. This is particularly useful for an oral dissolve form of administration due to the extended time of ALA exp...  
WO/2018/056461A1
The present invention addresses the issue of providing a means to ameliorate deterioration in the quality of preimplantation embryos as a result of aging, etc. The present invention pertains to an agent for improving the quality of eggs,...  
WO/2018/056409A1
The present invention addresses the problem of providing a preparation effective in preventing and/or ameliorating reduction in ovarian function. Provided is an agent for preventing or ameliorating reduction in ovarian function, comprisi...  
WO/2018/052848A1
Artificial cervical fluid is disclosed that contains a mucilaginous extract from the okra plant. The mucilaginous extract can be produced using a hot aqueous extractant or cold extraction process followed by separation of larger particle...  
WO/2018/041790A1
The present invention relates to an oral composition comprising one or more extracts originating from a plant material chosen from pollen and/or pistils originating from plants belonging to the Gramineae (Poaceae) and/or Pinaceae family....  
WO/2018/041268A1
Disclosed is a nanobody vaginal administration system, comprising a specific nanobody with biological activity and an antibody drug carrier that increases the stability and tissue penetrability of the nanobody, and the drug carrier inclu...  
WO/2018/035751A1
A Cordyceps sinensis health supplement containing traditional Chinese medicine extracts and a preparation method therefor. The health supplement comprises the following raw materials in parts by weight: 20-40 parts of Folium Mori extract...  
WO/2018/038180A1
The present invention addresses the problem of providing a technology that is useful for the progress in reproductive medicine and fertilized egg transplantation. Provided are: a sperm activator that contains, as an active ingredient, a ...  
WO/2018/034227A1
Provided is an anti-LAG-3 antibody that can be frequently administered to a non-rat animal. The anti-LAG-3 antibody comprises: (a) an L chain comprising an L-chain variable region that includes CDR1 having a QSLLDSDGNTY (SEQ ID NO. 16) a...  
WO/2018/033759A1
This invention relates to a dosage regimen comprising 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitri le and a combined oral contraceptive for use in the treatment of endometriosis in a non-pregnant, pre-menopausal female. T...  
WO/2018/030317A1
The present invention addresses the problem of providing a drug that reduces the risk of a reduction in bone mineral content associated with the hypoestrogenic effect, and that exhibits an excellent therapeutic effect with respect to end...  

Matches 1 - 50 out of 32,983